Brief: Arvinas- Due To Hart-Scott-Rodino Termination & Satisfaction Of Closing Conditions Of License Agreement, Asset Agreement, Novartis Pharma AG To Pay Co $150.0 Million
30/05/2024 23:26
Arvinas Inc ARVN.O :
* ARVINAS- DUE TO HART-SCOTT-RODINO TERMINATION &
SATISFACTION OF
CLOSING CONDITIONS OF LICENSE AGREEMENT, ASSET AGREEMENT,
NOVARTIS PHARMA AG TO PAY CO $150.0 MILLION
Source text for Eikon: ID:n0001655759-24-000069
Further company coverage: ARVN.O
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology